Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.

Arthritis and rheumatism - 1 Sept 2005

Tutuncu Zuhre, Kavanaugh Arthur, Zvaifler Nathan, Corr Maripat, Deutsch Reena, Boyle David

Abstract excerpt

OBJECTIVE: To determine whether polymorphisms in Fcgamma receptor type IIIA (FcgammaRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor alpha (TNFalpha) inhibitors. METHODS: The study group comprised 30 patients with RA and 5 patients with PsA. Patients were classified as being very good responders...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Psoriatic

Share to Etanercept

Share to Infliximab

Share to Joints

Share to Receptors, IgG

Share to Receptors, Tumor Necrosis Factor

Source

Identifiers

PMID: 16142749
DOI: 10.1002/art.21266

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.PMID 16142749Read ↗

Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.Semantic proximity Read ↗

The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.Semantic proximity Read ↗

Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis.Semantic proximity Read ↗

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.Semantic proximity Read ↗

Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.Semantic proximity Read ↗

Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups.Semantic proximity Read ↗

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.Semantic proximity Read ↗

FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.Semantic proximity Read ↗

Immunoglobulin G fc-receptor (FcgammaR) IIA, IIIA, and IIIB polymorphisms related to disease severity in rheumatoid arthritis.Semantic proximity Read ↗

TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis.Semantic proximity Read ↗

Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.Semantic proximity Read ↗

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.